- Home
- BMEA vs OBIO Comparison
BMEA vs OBIO Comparison
Compare BMEA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- OBIO
- Stock Information
- Founded
- BMEA 2017
- OBIO 2017
- Country
- BMEA United States
- OBIO United States
- Employees
- BMEA N/A
- OBIO N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- BMEA Health Care
- OBIO Health Care
- Exchange
- BMEA Nasdaq
- OBIO Nasdaq
- Market Cap
- BMEA 145.0M
- OBIO 156.6M
- IPO Year
- BMEA 2021
- OBIO N/A
- Fundamental
- Price
- BMEA $4.25
- OBIO $5.17
- Analyst Decision
- BMEA Buy
- OBIO Strong Buy
- Analyst Count
- BMEA 13
- OBIO 5
- Target Price
- BMEA $27.92
- OBIO $15.80
- AVG Volume (30 Days)
- BMEA 831.0K
- OBIO 182.8K
- Earning Date
- BMEA 10-29-2024
- OBIO 11-12-2024
- Dividend Yield
- BMEA N/A
- OBIO N/A
- EPS Growth
- BMEA N/A
- OBIO N/A
- EPS
- BMEA N/A
- OBIO N/A
- Revenue
- BMEA N/A
- OBIO $2,647,000.00
- Revenue This Year
- BMEA N/A
- OBIO $22.61
- Revenue Next Year
- BMEA N/A
- OBIO $16.64
- P/E Ratio
- BMEA N/A
- OBIO N/A
- Revenue Growth
- BMEA N/A
- OBIO N/A
- 52 Week Low
- BMEA $3.61
- OBIO $3.96
- 52 Week High
- BMEA $20.21
- OBIO $9.65
- Technical
- Relative Strength Index (RSI)
- BMEA 42.32
- OBIO 48.86
- Support Level
- BMEA $3.78
- OBIO $5.00
- Resistance Level
- BMEA $4.29
- OBIO $5.70
- Average True Range (ATR)
- BMEA 0.30
- OBIO 0.57
- MACD
- BMEA 0.15
- OBIO 0.03
- Stochastic Oscillator
- BMEA 89.71
- OBIO 51.71
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.